INDEX

SUBPART 58-2
BLOOD BANKS

November 7, 2007

A

A Cells in ABO grouping 58-2.3(f), 58-2.17(a)
ABO compatibility 58-2.7
    red cells components 58-2.9(c), 58-2.7, 58-2.17, 58-2.20(d)
ABO group 58-2.7
    allogeneic blood 58-2.3(f)
    autogeneic blood 58-2.3(f)
    confirmation of donor units 58-2.17(a)
    emergency release 58-2.17(c)
    label 58-2.6(d)
    neonates 58-2.20(d)
    recipient blood 58-2.17(a)
    records of test results 58-2.11(a), 58-2.12(a), 58-2.18(b)
    selection of components 58-2.9(c)
    required tests 58-2.3(f)
ABO incompatibility 58-2.7
    crossmatching to detect 58-2.17(c),(e)
Accidents 58-2.3(h), 58-2.8(b), 58-2.16(a), 58-2.27(h)
ACD anticoagulant 58-2.6(d)(2)
Adverse reactions
    blood donors 58-2.3(h)
    cytapheresis donors 58-2.15(c)
    serial plasmapheresis donors 58-2.14(e)
    transfusion recipients 58-2.16(a)
    reinfusion 58-2.27(h)
    standard operating procedures 58-2.8
Age
    allogeneic donors 58-2.2(c)
    autogeneic donors 58-2.2(e)
AIDS
    donor educational materials 58-2.2(d)
    donor screening 58-2.2(b)
    See also anti-HIV-1, anti-HIV-2, HIV
Alarms
    blood storage devices 58-2.6(g),(h),(j),
    blood warmers 58-2.8(c), 58-2.16(j), 58-2.25(b)
Albumin
    recordkeeping 58-2.19
Aliquots
    compatibility testing 58-2.9(ii), 58-2.17(f)
Allogeneic blood
    definition 58-2.1(p)
    donation criteria 58-2.2(b),(c),(d)
    frequency of collection 58-2.4(c)
    labeling 58-2.6(d)
    minimum hemoglobin/hematocrit 58-2.2(c)
    records of issuance 58-2.12
    specimen for testing 58-2.6(e)
    storage 58-2.6(g)
    testing 58-2.3(a),(f),(g), 58-2.9(b)
    volume 58-2.4(b)
Anti-D
    allogeneic donor testing 58-2.3(f)
    autogeneic donor testing 58-2.3(f)
    recipient testing 58-2.17(a)
Anti-HBC
    biohazard labeling 58-2.6(d)(3)(ii)(f)
    allogeneic donor testing 58-2.3(a), 58-2.9(b)
    autogeneic donor testing 58-2.3(a), 58-2.9(b)
    cytapheresis testing 58-2.3(a),(d),(e), 58-2.9(b)
    labeling 58-2.6(d)
    serial plasmapheresis testing 58-2.14(f)
    required test for 58-2.3(a)
    test controls 58-2.3(a)
Anti-HCV
    biohazard labeling 58-2.6(d)(3)(ii)(f)
    allogeneic donor testing 58-2.3(a), 58-2.9(b)
    autogeneic donor testing 58-2.3(a), 58-2.9(b)
    cytapheresis testing 58-2.3(a),(d),(e)
    labeling 58-2.6(d)
    serial plasmapheresis testing 58-2.14(f)
    test controls 58-2.3(a)
Anti-HIV-1
    biohazard labeling 58-2.6(d)(3)(ii)(f)
    allogeneic donor testing 58-2.3(a), 58-2.9(b)
    autogeneic donor testing 58-2.3(a), 58-2.9(b)
    controls 58-2.3(a)
    cytapheresis testing 58-2.3(a),(d),(e)
    incomplete test results 58-2.3(b)
    notification of test results 58-2.23
    serial plasmapheresis testing 58-2.14(f)
    reporting of test results 58-2.3(b)
    required testing for 58-2.3(a)
    weak reactive control 58-2.3(b)
    verification of test results 58-2.3(b)
Anti-HIV-2
    biohazard labeling 58-2.6(d)(3)(ii)(f)
    allogeneic donor testing 58-2.3(a), 58-2.9(b)
    autogeneic donor testing 58-2.3(a), 58-2.9(b)
Anti-HIV-2 (cont)
cytapheresis testing 58-2.3(a),(d),(e)
notification of test results 58-2.23
serial plasmapheresis testing 58-2.14(f)
reporting of test results 58-2.3(b)
required testing for 58-2.3(a)
test controls 58-2.3(a)
Anti-HTLV-I/II
biohazard labeling 58-2.6(d)(3)(ii)(f)
allogeneic donor testing 58-2.3(a), 58-2.9(b)
autogeneic donor testing 58-2.3(a), 58-2.9(b)
controls 58-2.3(a)
cytapheresis testing 58-2.3(a),(d),(e)
serial plasmapheresis testing 58-2.14(f)
required testing 58-2.3(a)
Antibodies
testing allogeneic donors 58-2.3(g)
testing recipients 58-2.17(b)
unexpected – See unexpected antibodies
Anticoagulants 58-2.6(b),(d)
Antiglobulin testing 58-2.7
unexpected antibodies 58-2.17(b)
crossmatching 58-2.7, 58-2.17(c)
Apheresis – See cytapheresis, serial plasmapheresis
Aspirin
ingestion by cytapheresis donors 58-2.15(c)
At-risk behavior of donors 58-2.2(b),(c),(d)
Autogeneic blood
biohazard labeling 58-2.6(d)(3)(ii)(f)
definition 58-2.1(q)
donation criteria 58-2.2(e),(f)
frequency of collection 58-2.2(e)
labeling 58-2.6(d)
minimum hemoglobin/hematocrit 58-2.2(e)
positive test result - release of 58-2.9(b)
procedures to encourage the use of 58-2.16(i)
records of issuance 58-2.12
required tests 58-2.3(a)
shipping 58-2.6(m)
 specimens for testing 58-2.6(e)
storage 58-2.6(g)
testing 58-2.3(a),(f)
volume 58-2.4(b)
Autologous blood – See autogeneic blood

Blood bank
definition 58-2.1(a)
Blood collection 58-2.4, 58-2.6(f)
Blood collection systems
minimum requirements 58-2.6(d)
Blood components
administration 58-2.16(d)
definition 58-2.1(d)
expiration 58-2.6(f),(h),(j)
issuance of 58-2.6(f) through 58-2.6(l), 58-2.9
labeling 58-2.6(d)
preparation 58-2.6(f)
records of issuance 58-2.12
storage 58-2.6(d)(2), 58-2.6(f) through (j), (l) and (m)
transportation 58-2.6(g),(m), 58-2.9(a)
Blood derivatives
administration 58-2.16(d)
definition 58-2.1(e)
issuance 58-2.9
records of issuance 58-2.12
Blood donation center 58-2.13
definition 58-2.1(b)
Blood pressure
donors 58-2.2(c)
Blood products
definition 58-2.1(f)
Blood recovery 58-2.25
Blood samples – See samples
Blood Services Activity Report 58-2.10(b), 58-2.11(b)
Blood warming 58-2.16(j)
standard operating procedure 58-2.8(c), 58-2.16(j)
intraoperative and postoperative 58-2.25(b)

C
Care of
blood donors 58-2.2
cytapheresis donors 58-2.15(c)
serial plasmapheresis donors 58-2.14(e)
Centrifuges
calibration of 58-2.7(e)
Circular of information 58-2.6(d),(n)
Coagulation factor concentrates
investigation of reactions 58-2.12(c)
records 58-2.12(b)
Collection of blood components by apheresis
58-2.4, 58-2.6, 58-2.13 (d)
care of donor 58-2.15(c)
consent 58-2.15(b)

B
B Cells in ABO grouping 58-2.3(f), 58-2.17(a), 58-2.20(d)
Collection of blood components by apheresis (cont)
- definition 58-2.1(i)
- direction 58-2.15(c)
- donor selection 58-2.15(a),(c)
- double red cell pheresis 58-2.15(d)
- issuance 58-2.9(b)
- multiple patient-dedicated 58-2.3(e)
- physician availability 58-2.15(c)
- procedure 58-2.15(f)
- qualifications and care of donor 58-2.15(c)
- red cell, double pheresis 58-2.15(d)
- red cell loss 58-2.15(d)
- release 58-2.9(b)
- required tests 58-2.3
- return of rbc 58-2.15
- records 58-2.15(g)
- supervision 58-2.15(c)
- testing 58-2.3(a),(d),(e), 58-2.9(b)
- training 58-2.15(c)
- volume and frequency 58-2.15(d)

Compatibility testing
- blood and blood components 58-2.7(a), 58-2.17(a),(c)
- neonates 58-2.20(d)
- emergency issue 58-2.8(c), 58-2.9(c), 58-2.17(c), 58-2.18(h)
- massive transfusion 58-2.17(c)
- procedure 58-2.17(e)
- recordkeeping 58-2.12(a)
- reservation of blood 58-2.16(c)
- samples 58-2.6(e), 58-2.17(d)

Computer system
- validation 58-2.17(a)

Confidential unit exclusion 58-2.2(d)
Confidentiality of records 58-2.10

Confirmation
- patient identity prior to reinfusion 58-2.27(g)
- patient identity prior to transfusion 58-2.16(f)

Consent
- allogeneic 58-2.4(a)
- autogeneic 58-2.2(a), 58-2.4(a)
- cytapheresis 58-2.15(b)
- exceptions 58-2.26(a)
- HIV testing 58-2.4(a)
- minors 58-2.2(c)
- out of hospital transfusion 58-2.21(c)
- serial plasmapheresis 58-2.14(c),(j)
- release of information 58-2.10

Containers
- blood collection 58-2.6(a)
- cytapheresis 58-2.15(f)
- infectious waste 58-2.21(f)
- serial plasmapheresis 58-2.14(h),(i)
- reinfusion 58-2.27(e)

Contamination
- protection against 58-2.2(b), 58-2.6(d),(f)
- visual inspection 58-2.9(d)

Coolant
- suitable 58-2.9(j)

CPD anticoagulant 58-2.6(d)(2)
CPDA-1
- anticoagulant 58-2.6(d)(2)
- crossmatching 58-2.6(e)

Crossmatching – See compatibility testing

Cryoprecipitate
- expiration 58-2.6(f),(h)
- Factor VIII replacement 58-2.6(f)
- storage 58-2.6(h)
- thawing 58-2.6(f), 58-2.6(l)

Cytapheresis – See collection of blood components by apheresis

Cytomegalovirus (CMV)
- CMV negative products 58-2.16(a)

D

D antigen
- donor testing 58-2.3(f)
- recipient testing 58-2.17(a)

Deferral records 58-2.9(l), 58-2.11(h)
Definitions 58-2.1

Deglycerolized red blood cells
- expiration 58-2.6(f),(j)
- storage 58-2.6(g)

Department
- definition 58-2.1(t)

Derivatives
- definition 58-2.1(e)
- recordkeeping 58-2.12(b),(c), 58-2.19

Directed donation – See allogeneic blood
- definition 58-2.1(r)

Director of transfusion services
- responsibilities 58-2.16(a)

Disease transmission
- donor notification 58-2.23
- screening to prevent 58-2.2
- testing to prevent 58-2.3

Disposal
- expired units 58-2.24
- unaccepteble units 58-2.3(b)
- untransfused units 58-2.24

Disposition of
- blood for transfusion 58-2.6(m)
- recovered blood 58-2.6(m)

Disposition records
- collection 58-2.11

Donation interval
allogeneic 58-2.4(c)
Donation interval (cont)
autogeneic 58-2.2(e)
cytopheresis 58-2.15(d)
Donation quantity 58-2.4(b)
Donor definition 58-2.1(c)
Donor testing 58-2.3
Donor deferral 58-2.9(l), 58-2.11(h)
Donors
allogeneic – See allogeneic blood
autogeneic – See autogeneic blood
cytopheresis 58-2.15
Donor testing 58-2.3
Donor deferral 58-2.9(l), 58-2.11(h)
Drugs
addition to blood 58-2.16(e)
cytopheresis donors 58-2.15(b),(c)
serial plasmapheresis donors 58-2.14(c)
Generic
allogeneic 58-2.4(c)
autogeneic 58-2.2(e)
cytopheresis 58-2.15(d)
serial plasmapheresis 58-2.14(e)
records of collection 58-2.11
selection criteria 58-2.2
Educational material for donors 58-2.2(d)(1)
Emergency issue of blood 58-2.3(a), 58-2.8(c),
58-2.9(a),(b),(g), 58-2.17(c), 58-2.18(h)
exceptions 58-2.26(b)
Frequency of donation
allogeneic 58-2.4(c)
autogeneic 58-2.2(e)
cytopheresis 58-2.15(d), (e)
serial plasmapheresis 58-2.14(g)
Expired Units
disposal 58-2.24
storage 58-2.24
Food and Drug Administration
approved additive solutions 58-2.6(d)
compliance 58-2.7(a)
criteria for containers, anticoagulants and reagents 58-2.6(d)
definition 58-2.1(k)
Freezers
alarms 58-2.6(h),(j)
cryoprecipitate storage 58-2.6(h)
frozen red blood cell storage 58-2.6(j)
plasma storage 58-2.6(h)
temperature recording 58-2.6(h),(j)
Frequency of donation
allogeneic 58-2.4(c)
autogeneic 58-2.2(e)
cytopheresis 58-2.15(d), (e)
serial plasmapheresis 58-2.14(g)
Fresh frozen plasma
expiration 58-2.6(f),(h)
refreezing prohibited 58-2.6(h)
storage 58-2.6(f), 58-2.6(h)
thawing 58-2.6(f), 58-2.6(l)
Frozen red blood cells
expiration 58-2.6(f),(j)
reinfusion prohibited 58-2.6(h)
storage 58-2.6(j)
thawing 58-2.6(f),(j),(l)
Granulocytes
blood component 58-2.1(d)
cytopheresis 58-2.15
Growth hormone
donors 58-2.2(c)(11)
Hemapheresis 58-2.1(i), 58-2.14(b)
See also collection of blood components by apheresis 58-2.15, and

FBP – See fresh frozen plasma
Filters for transfusion 58-2.16(d)
Frequency of donation
allogeneic 58-2.4(c)
autogeneic 58-2.2(e)
cytopheresis 58-2.15(d),(e)
serial plasmapheresis 58-2.14(g)
Fresh frozen plasma
expiration 58-2.6(f),(h)
refreezing prohibited 58-2.6(h)
storage 58-2.6(f), 58-2.6(h)
thawing 58-2.6(f), 58-2.6(l)
Frozen red blood cells
expiration 58-2.6(f),(j)
reinfusion prohibited 58-2.6(h)
storage 58-2.6(j)
thawing 58-2.6(f),(j),(l)
Granulocytes
blood component 58-2.1(d)
cytopheresis 58-2.15
Growth hormone
donors 58-2.2(c)(11)
Hemapheresis 58-2.1(i), 58-2.14(b)
See also collection of blood components by apheresis 58-2.15, and
Hematocrit
- allogeneic donors 58-2.2(c)
- autogeneic donors 58-2.2(e),(f)
- recordkeeping 58-2.11(e)

Hemodilution – See isovolemic hemodilution

Hemoglobin
- allogeneic donors 58-2.2(c)
- autogeneic donors 58-2.2(e),(f)
- recordkeeping 58-2.11(e)

Heparin
- anticoagulant 58-2.6(d)(2)

Hepatitis
- biohazard labeling 58-2.6(d)(3)(ii)(f)
- controls 58-2.3(a)
- donor history 58-2.2(b)
- labeling 58-2.6(d)
- nucleic acid testing for HCV 58-2.3(a)
- required testing 58-2.3(a)
- testing allogeneic donors 58-2.3(a), 58-2.9(b)
- testing autogeneic donors 58-2.3(a), 58-2.9(b)
- testing cytapheresis donors 58-2.3(a),(d),(e)
- testing serial plasmapheresis 58-2.14(f)

HIV – See also anti-HIV-1 and anti-HIV-2
- donor screening 58-2.2(b)
- education 58-2.2(d)(1)
- labeling 58-2.6(d)(3)
- nucleic acid testing for HIV 58-2.3(a)
- testing results 58-2.23
- testing for 58-2.3(a)

Holding facility 58-2.22
- definition 58-2.1(m)

Homologous – See allogeneic blood

HTLV-I/II – See anti-HTLV-I/II

Human growth factor
- donor deferral 58-2.2(c)

Identification
- blood prior to transfusion 58-2.16(f)
- recipient before transfusion 58-2.16(f)
- red cells from manual pheresis prior to reinfusion 58-2.14(h)
- samples for reinfusion 58-2.27(g)

Identification number for donor units 58-2.6(d)

Illegal injectable drug use in donors 58-2.6(d)

Immunohematology testing 58-2.7

Incident reporting
- collection 58-2.3(h)
- reinfusion 58-2.27(h)

transfusion 58-2.16(a)
procedure manual 58-2.8(b)

Informed consent – See consent

Inspection of blood products
- prior to issuance 58-2.8(c), 58-2.9(d)

Institution
- definition 58-2.1(a)

Intraoperative blood recovery
- definition 58-2.1(j)
- identification procedures 58-2.25(d)
- methods 58-2.25(b)
- protocol for 58-2.25(c)
- recordkeeping 58-2.25(i)
- storage 58-2.25(e)
- transfusion 58-2.25(a),(e)
- untested units 58-2.25(g)

Irradiation
- labeling of irradiated products 58-2.6(k)
- maintenance 58-2.6(k)
- protocol 58-2.6(k)
- responsibility 58-2.6(k)

Isovolemic hemodilution – See normovolemic hemodilution

Issuance of blood, components, derivatives
- emergency 58-2.6, 58-2.9
- inspection prior to transfusion 58-2.9(d)
- NYS-approved sites 58-26(m)
- order for 58-2.9(c)
- records 58-2.9(h), 58-2.12
- records of issuance 58-2.12
- reissue 58-2.9(j)
- responsibility 58-2.16(a)(3)
- retention of blood samples 58-2.9(i)
- return unit to blood bank 58-2.9(h),(j)
- sequence of issuance 58-2.9(k)
- transportation container 58-2.9(h)
- urgent requirement 58-2.9(g)

L

Labeling
- ABO group 58-2.6(d)
- allogeneic 58-2.6(d)
- at collection 58-2.6(d)
- autogeneic 58-2.6(d),(g)
- biohazard 58-2.6(d)(3)(ii)(f)
- blood or blood components 58-2.9(k)
- donor identification number 58-2.6(d)
- pilot blood specimen 58-2.6(d)
- pre-transfusion specimens 58-2.7(a)
- Rh group 58-2.6(d)
- relabeling of components 58-2.6(h)
- shipping container 58-2.9(h)
- test results 58-2.6(d)
testing not completed 58-2.9(b)
unacceptable test results 58-2.3(a)
Laboratory permit 58-2.6(a)
Licensed practical nurses 58-2.16(d)
Limited transfusion service
agreement 58-2.21(b)
availability of MD 58-2.21(e)
coverage, 24-hour-a-day 58-2.16(h)
definition 58-2.1(l)
medical supervision 58-2.21(d)
out-of-hospital transfusions 58-2.21(c)
patient requirements 58-2.21(c)
recordkeeping 58-2.12

M

Malaria
Donor history 58-2.2(b)
Manufacturer’s instructions
compliance with 58-2.7(c)
Massive transfusion 58-2.17(c)
Medical director
allogeneic donation 58-2.2(a), 58-2.6(a)
autogeneic donation 58-2.2(e), 58-2.6(a)
definition 58-2.1(s)
direction 58-2.6(a)
Medical services
care of donor 58-2.6(a)
Medications added to blood 58-2.16(e)
Microscopes
maintenance 58-2.7(d)
use of 58-2.7(d)
Minors
blood donation 58-2.2(c)

N

Neonatal transfusion 58-2.20, 58-2.17(d)
Normovolemic hemodilution
definition 58-2.1(j),lv
identification procedures 58-2.25(d)
methods 58-2.25(b)
protocol 58-2.25(c)
recordkeeping 58-2.25(l)
storage 58-2.25(f)
transfusion 58-2.25(a)
untested units 58-2.25(g)
Notification
HIV-1 and HIV-2 test results 58-2.23

Open system 58-2.6(f)
Ordering blood components 58-2.9(c)
Ordering blood derivatives 58-2.9(c)
Out-of-hospital transfusions – See limited
transfusion services

P

Permits
blood collection 58-2.6(a)
for required testing 58-2.3(a)
Pheresis – See cytophoresis, serial plasmapheresis
Phlebotomy
apparatus 58-2.6(b)
records of collections 58-2.11
phlebotomy sites 58-2.6(c)
Physician
approval for autogeneic donation
58-2.2(a),e
order for transfusion 58-2.9(c)
out-of-hospital transfusion 58-2.21(d),e
See also medical director
Plasma – See fresh frozen plasma
fractionation 58-2.3(c), 58-2.9(b)
Plasma derivatives
definition 58-2.1(e)
recordkeeping 58-2.19
Plasmapheresis – See serial plasmapheresis
Platelets
donated by infant’s mother 58-2.3(d)
storage 58-2.6(g),i
Pooling blood components 58-2.9(f)
Postoperative recovery
definition 58-2.1(j)
identification procedures 58-2.25(d)
methods 58-2.25(b)
protocol 58-2.25(c)
Postoperative recovery
recordkeeping 58-2.25(i)
storage 58-2.25(e)
transfusion 58-2.25(a),(h)
untested units 58-2.25(e)
Procedure manual 58-2.8
Pulse
donors 58-2.2(c)

Q

Quality control
recordkeeping 58-2.7(d)
testing 58-2.7(b),(c),(d)
Quantity
allogeneic donation 58-2.4(b)
atogeneic donation 58-2.4(b)
Quarantine
unacceptable blood 58-2.3(a)
untested blood 58-2.3(a)

R

Reactions – See also incident reporting
conclusions signed by director 58-2.12(a)
records to be kept by blood bank 58-2.12,
58-2.18, 58-2.19
records to be kept on patient chart
58-2.18, 58-2.19

Reagents
ABO grouping 58-2.3(f), 58-2.17(a)
antibody detection 58-2.3(g), 58-2.17(b)
manufacturer’s instructions 58-2.7(b)
records 58-2.7(d)
Rh grouping 58-2.3(f), 58-2.17(a)
storage 58-2.6(g), 58-2.7(b)

Recipient
blood sample retention 58-2.17(f)
blood testing 58-2.7, 58-2.17
identification of prior to transfusion
58-2.16(f)

Records
confidentiality 58-2.10
deferral 58-2.9(l), 58-2.11(h)
coagulation factor concentrates
58-2.12(b), 58-2.12(c)
collection 58-2.11
cytapheresis 58-2.15(g)
infusions 58-2.19
issuance for transfusion 58-2.12
plasma derivative infusion 58-2.19
required 58-2.10
retention of 58-2.10
serial plasmapheresis 58-2.14(j)
temperature 58-2.6, 58-2.16(j)

Red blood cells
deglycerolized 58-2.6(f),(g),(j)
double red cell pheresis 58-2.15(d)
expiration 58-2.6
frozen 58-2.6(j)
storage of 58-2.6(g), 58-2.9(j)

Refrigerators
alarms 58-2.6(g)
blood storage 58-2.6(g)
temperature recording 58-2.6(g)

Reinfusion 58-2.27
definition 58-2.1(u)
errors 58-2.27(h)
labeling 58-2.27(c), 58-2.27(e)
permit 58-2.27(f)
positive identification prior to reinfusion
58-2.27(g)
retention of records 58-2.27(i)
review 58-2.27(b)
storage 58-2.27(d)

Reissue of blood 58-2.9(j)

Respiratory diseases
donors 58-2.2(b)

Responsibility for
blood collected by phlebotomy 58-2.6(m)
blood intended for transfusion 58-2.6(m)
limited transfusion 58-2.21(b)
procedure manuals 58-2.8
recovered blood 58-2.6(m)
reinfusion 58-2.27
required tests 58-2.3(f)
testing 58-2.3(b), 58-2.7(b)
transfusion committee 58-2.16
transfusion services 58-2.16(a)

Retention
compatibility samples 58-2.17(f)
blood issued for transfusion 58-2.9(i)
records 58-2.10, 58-2.11(a)
temperature records 58-2.6, 58-2.16(j)

Rh group
confirmation 58-2.17(a)
labeling 58-2.6(d)
allogeneic collections 58-2.3(f)
autogeneic collections 58-2.3(f)
neonates 58-2.20
recipients 58-2.17(a)
required tests 58-2.3(f)
selecting blood for transfusion 58-2.9(c)
testing 58-2.7, 58-2.17
weak D 58-2.3(f)

S

Saline – See sodium chloride

Samples
blood issued for transfusion 58-2.9(i)
donor testing 58-2.6(e)
labeling pilot samples 58-2.6(d)(3)(i)
pretransfusion 58-2.17(f)
storage of 58-2.6(g)

Seal
closed system 58-2.6(d)
open system 58-2.6(f)

Selection criteria
allogeneic donors 58-2.2
autogeneic donors 58-2.2
cytapheresis donors 58-2.15
serial plasmapheresis donors 58-2.14

Self-exclusion 58-2.2(d)

Serial Plasmapheresis
automated procedure 58-2.14(i)
care of donor 58-2.14(e)
consent 58-2.14(c)
definition 58-2.1(g),(h)
direction 58-2.14(b)
donor selection 58-2.14(a),(d)
Serial plasmapheresis (cont)
donor testing 58-2.14(f)
laboratory testing 58-2.14(f)
manual procedure 58-2.14(h)
physician availability 58-2.14(e)
records 58-2.14(j)
return of red cells 58-2.14(g)
serial 58-2.14(e)
standards 58-2.14(a)
supervision 58-2.14(e)
training 58-2.14(e)
Sexually transmitted diseases
donors 58-2.2(b)
Skin
diseases in donors 58-2.2(b)
lesions in donors 58-2.2(b)
Sodium chloride 0.9%
 intraoperative blood recovery 58-2.25(e)
transfusion 58-2.16(e)
SOPM 58-2.8
Specimens
allogeneic donor testing 58-2.6(e)
autogeneic donor testing 58-2.6(e)
compatibility testing 58-2.6(e), 58-2.17(f)
58-2.7(a),(b),(d)
storage of 58-2.6(g)
Standard operating procedures 58-2.8
Sterile connecting device 58-2.6(f)
Sterility of equipment 58-2.5, 58-2.6(b)
Storage of blood – See individual components
Supervision
cytapheresis 58-2.15(c)
serial plasmapheresis 58-2.14(e)
Syphilis
allogeneic donor testing 58-2.3(a), 58-2.9(b)
autogeneic donor testing 58-2.3(a), 58-2.9(b)
biohazard labeling 58-2.6(d)(3)(ii)(f)
controls 58-2.3(a)
cytapheresis donor testing 58-2.3(a),(d),(e)
donor history 58-2.2(b)
labeling 58-2.6(d)
required laboratory test 58-2.3
serial plasmapheresis donor testing 58-2.9(b), 58-2.14(f)
Temperature, storage
blood in transit 58-2.6(g)
cryoprecipitate 58-2.6(h)
deglycerolized red cells 58-2.6(g)
fresh frozen plasma 58-2.6(f),(l)
frozen red cells 58-2.6(f),(l)
platelets 58-2.6(i)
records of 58-2.6
red cells 58-2.6(g), 58-2.9(j)
whole blood 58-2.6(g)
Temperature for warming blood 58-2.16(j), 58-2.25(b)
Temperature of donor 58-2.2(c)
Testing
ABO group 58-2.3(f), 58-2.7(b), 58-2.17(a)
algorithms 58-2.3(b)
allogeneic blood 58-2.3, 58-2.9(b)
antibody screening 58-2.3(g), 58-2.7(b), 58-2.17(b)
autogeneic blood 58-2.3
compatibility 58-2.7(a),(b), 58-2.17(c)
controls 58-2.3(a)
cytapheresis 58-2.3, 58-2.9(b)
immunohematology 58-2.7
neonatal 58-2.20
notification of donor HIV results 58-2.23
Rh group 58-2.3(f), 58-2.7, 58-2.17(a)
recipient blood 58-2.7, 58-2.17
records 58-2.10
reports 58-2.3(a) 58-2.3(b)
results 58-2.3(a), 58-2.3(b)
serial plasmapheresis donors 58-2.14
Thawing
cryoprecipitate 58-2.6(f),(l)
fresh frozen plasma 58-2.6(f),(l)
frozen red cells 58-2.6(f),(l)
Therapeutic procedures 58-2.2(g)
Transfusion
availability of person administering the transfusion 58-2.16(f)
committee 58-2.16(b)
donor history 58-2.2(c)
identification of recipient and blood to be transfused 58-2.16(f)
limited transfusion 58-2.21
massive 58-2.17(c)
neonatal 58-2.20
outside health care setting 58-2.16(g)
qualifications of personnel 58-2.16(d)
reinfusion 58-2.27
required records 58-2.18
plasma derivatives 58-2.19
required standards for 58-2.16(a)
Transfusion committee 58-2.16(b)
composition of 58-2.16(b)
procedures 58-2.16(b), 58-2.16(i)
reservation of blood 58-2.16(c)

Transfusion complications
reporting 58-2.16(a)
records 58-2.12(a),(c), 58-2.18(f), 58-2.19(d)
See also errors

Transfusion service
definition 58-2.1(n)
responsibility of director 58-2.16(a)

Transportation
authorization 58-2.6(m)
container 58-2.9(a)
See individual components

Tuberculosis
donor history 58-2.2(b)


U

Unacceptable test results 58-2.3(a), 58-2.9(b)
Unexpected antibodies
neonates 58-2.20
samples 58-2.17(d)
testing allogeneic blood 58-2.3(g)
testing recipients 58-2.17(b)
Untested blood 58-2.9(b)

V

Validation
computer system 58-2.17(a)

Venipuncture
preparation of site 58-2.6(c)

Viral hepatitis
donor history 58-2.2(b)

Volume
allogeneic blood collection 58-2.4(b)
autogeneic blood collection 58-2.4(b)
within 8-week period 58-2.4(c)

W

Warming
reinfusion 58-2.25(b)
transfusion 58-2.16(j)

Weight
donor 58-2.2(c)

Whole blood
issuance 58-2.9(d)
preparation of platelets 58-2.6(g)